NRG-HN001

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

For more information about this clinical trial, click here

Schema & Eligibility NRG-HN001

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Phelps County Regional Medical Center, Rolla, MO
Mercy Hospital, St. Louis, MO
St. Louis Cancer & Breast Institute, St. Louis, MO
Good Samaritan Regional Health Center, Mt. Vernon, IL